CCX354 is a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).
ChemoCentryx reported positive results from a Phase II clinical trial with CCX354 which evaluated the safety, tolerability, clinical and biological activity of this compound in patients with RA.
As per the agreement with GSK, ChemoCentryx will receive an option exercise fee of $25m and will be eligible for further regulatory and sales milestone payments.
GSK will now be solely responsible for funding further clinical development and commercialization for CCX354 worldwide.